Table 4.
Adverse effects of liposomal irinotecan.
Reproduced with permission from [69]
| Most common grade 3–4 adverse events | ||||||
|---|---|---|---|---|---|---|
| PEPO2 | Irinotecan | Docetaxel | ||||
| N | % | n | % | n | % | |
| Anaemia | 2 | 4.5 | 2 | 4.5 | 3 | 6.8 |
| Neutropaenia | 5 | 11.4 | 7 | 15.9 | 2 | 2.6 |
| Thrombocytopenia | 1 | 2.3 | 1 | 2.3 | 0 | 0 |
| Febrile neutropenia | 3 | 6.8 | 5 | 11.3 | 2 | 2.6 |
| Diarrhoea | 12 | 27.3 | 8 | 18.2 | 1 | 2.3 |
| Nausea | 5 | 11.4 | 2 | 4.6 | 0 | 0 |
| Vomiting | 2 | 4.6 | 6 | 13.6 | 3 | 6.8 |
| Anorexia | 3 | 6.8 | 3 | 6.8 | 0 | 0 |
| Fatigue | 2 | 4.6 | 1 | 2.3 | 1 | 2.3 |
Most common grade 3–5 adverse events observed in a phase II study of liposomal irinotecan (PEP02), comprised of a liposomal irinotecan, irinotecan, and docetaxel arm